DNAJC22 (DnaJ Heat Shock Protein Family (Hsp40) Member C22) encodes a member of the DnaJ/Hsp40 family of co-chaperones. DNAJC22 functions as a co-chaperone that assists Hsp70 proteins in protein folding, quality control, and degradation processes. Research has implicated DNAJC22 variants in Parkinson's Disease risk, and the gene plays important roles in protein homeostasis maintenance in neurons.
| Attribute |
Value |
| Gene Symbol |
DNAJC22 |
| Full Name |
DnaJ Heat Shock Protein Family (Hsp40) Member C22 |
| Aliases |
DJC22, Hsp40 |
| Chromosomal Location |
12q24.11 |
| NCBI Gene ID |
79982 |
| Ensembl ID |
ENSG00000155792 |
| UniProt ID |
Q8T5M0 |
DNAJC22 is a member of the DnaJ/Hsp40 protein family, which serves as co-chaperones for Hsp70 proteins. The family is characterized by the presence of a J-domain that stimulates Hsp70 ATPase activity [1][2]. DNAJC22 participates in several cellular processes:
DNAJC22 functions in the protein quality control network:
- Co-chaperone activity: The J-domain interacts with Hsp70/Hsc70 proteins, stimulating their ATPase activity
- Protein folding assistance: Helps nascent polypeptides achieve proper conformation
- Misfolded protein handling: Targets improperly folded proteins for refolding or degradation
- ERAD pathway: Participates in endoplasmic reticulum-associated degradation
- Mitochondrial protein quality control: May assist mitochondrial protein homeostasis
¶ Cellular Localization and Expression
- Expressed in various tissues including brain, heart, liver, and kidney
- Moderate expression in neuronal tissues
- Localizes to cytoplasm and potentially ER compartments
- Induced under proteotoxic stress conditions
A large case-control study (PMID: 35715682) examined genetic variants in HSP40/DNAJ family genes in Parkinson's Disease [3]. The study found that:
- DNAJ family genes, including DNAJC22, show association with PD risk
- Variants in these co-chaperone genes may contribute to impaired protein quality control
- Dysfunction in protein homeostasis is a key mechanism in PD pathogenesis
The involvement of DNAJC22 in PD aligns with the broader role of J-protein dysfunction in alpha-synuclein aggregation and dopaminergic neuron survival.
DNAJC22 may play a role in Alzheimer's Disease through:
- Protein homeostasis maintenance relevant to amyloid processing
- Potential involvement in tau pathology
- General proteostatic stress response in neurons
Some studies suggest DNAJC22 dysregulation in certain cancers, possibly related to altered protein metabolism in proliferating cells.
DNAJC22 may be relevant to ALS through:
- Protein homeostasis in motor neurons
- ER stress response mechanisms
- Potential interactions with ALS-related proteins
- General vulnerability of protein quality control in motor neurons
DNAJC22 involvement in HD is being explored:
- Role in mutant huntingtin clearance
- Interaction with autophagy pathways
- General protein quality control in striatal neurons
¶ J-Domain Function
DNAJC22 contains the characteristic J-domain that enables interaction with Hsp70 family proteins:
- The J-domain (~70 amino acids) contains the highly conserved HPD motif
- This domain stimulates Hsp70 ATP hydrolysis, converting it to the high-affinity state
- Substrate binding and release cycles are regulated through this mechanism
The C-terminal domain of DNAJC22:
- Recognizes specific client proteins
- Determines substrate specificity
- Works in concert with Hsp70 for protein refolding
In neurons, DNAJC22 contributes to:
- Synaptic protein homeostasis: Maintains proper folding of synaptic proteins
- ER stress management: Coordinates with ER-resident quality control systems
- Mitochondrial quality control: Assists in mitochondrial protein turnover
- Proteotoxic stress response: Activates under conditions of protein aggregation
DNAJC22 belongs to the DNAJ family subcategory C (DNAJC), which typically includes:
- N-terminal J-domain
- Gly/Phe-rich region
- C-terminal client-binding domain
- Variable C-terminal regions that determine client specificity
¶ Domain Architecture
| Domain |
Position |
Function |
| J-domain |
N-terminal (~70 aa) |
Hsp70 interaction and activation |
| Gly/Phe-rich |
Middle |
Flexible linker region |
| Client-binding |
C-terminal |
Substrate recognition |
- Conserved HPD motif in J-domain (positions 34-36)
- Potential for homodimerization
- Targeting signals for cellular localization
DNAJC22 is expressed in various brain regions:
- Cerebral cortex (pyramidal neurons)
- Hippocampus (CA regions, dentate gyrus)
- Basal ganglia (striatum)
- Cerebellum (Purkinje cells)
- Brainstem nuclei
- Cytoplasm: Primary location for co-chaperone function
- Endoplasmic reticulum: ER-associated degradation participation
- Mitochondria: Potential mitochondrial protein quality control
- Nucleus: May have nuclear functions in stress response
DNAJC22 expression is regulated by:
- Heat shock factor (HSF1): Induced under proteotoxic stress
- Developmental stage: Differential expression across development
- Cellular stress: Upregulated under various stress conditions
Targeting protein quality control pathways including DNAJC22 represents a therapeutic strategy:
- Enhancing co-chaperone function could improve alpha-synuclein clearance
- Small molecules to modulate J-protein activity are under investigation
- Gene therapy approaches to increase DNAJC22 expression are being explored
Several approaches are being developed to target J-protein function:
- Hsp70 activators: Compounds that enhance Hsp70 activity, which DNAJC22 modulates
- J-domain mimetics: Peptide-based approaches to enhance co-chaperone function
- Autophagy enhancers: Since protein quality control intersects with autophagy pathways
- Proteostasis modulators: Broader approaches to enhance protein homeostasis
Viral vector-mediated delivery of DNAJC22:
- AAV-based gene delivery to target neurons
- Promoter selection for neuron-specific expression
- Combination approaches targeting multiple quality control genes
- Challenges with achieving proper subcellular localization
Therapeutic potential lies in combining DNAJC22 targeting with:
- Autophagy enhancers (rapamycin, trehalose)
- Hsp70 modulators
- Anti-aggregant compounds
- Gene therapy for other PD genes
GWAS and sequencing studies continue to identify DNAJC22 variants:
- Rare coding variants in PD cohorts
- Regulatory variants affecting expression
- Interaction effects with other Parkinson's risk genes
- Population-specific variants
Current research focuses on:
- DNAJC22 knockdown/knockout phenotypes in neuronal models
- Interaction networks with other DNAJ proteins
- Role in specific forms of alpha-synuclein pathology
- Mitochondrial quality control contributions
Key experimental approaches:
- Cell culture: Neuronal cell lines with DNAJC22 modulation
- Animal models: Knockout/knockin mouse models
- Induced neurons: Patient-derived iPSC neurons
- Organoids: Brain organoid models for protein aggregation
- Precise client protein specificity of DNAJC22
- Relative importance compared to other DNAJ proteins
- Therapeutic window for enhancement approaches
- Biomarker potential for PD progression
Targeting protein quality control pathways including DNAJC22 represents a therapeutic strategy:
- Enhancing co-chaperone function could improve alpha-synuclein clearance
- Small molecules to modulate J-protein activity are under investigation
- Gene therapy approaches to increase DNAJC22 expression are being explored
Several approaches are being developed to target J-protein function:
- Hsp70 activators: Compounds that enhance Hsp70 activity, which DNAJC22 modulates
- J-domain mimetics: Peptide-based approaches to enhance co-chaperone function
- Autophagy enhancers: Since protein quality control intersects with autophagy pathways
Viral vector-mediated delivery of DNAJC22:
- AAV-based gene delivery to target neurons
- Promoter selection for neuron-specific expression
- Combination approaches targeting multiple quality control genes
GWAS and sequencing studies continue to identify DNAJC22 variants:
- Rare coding variants in PD cohorts
- Regulatory variants affecting expression
- Interaction effects with other Parkinson's risk genes
Current research focuses on:
- DNAJC22 knockdown/knockout phenotypes in neuronal models
- Interaction networks with other DNAJ proteins
- Role in specific forms of alpha-synuclein pathology